| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology
Biomarker discovery market estimated by third party research to be $51.5 billion in 2024
PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology.
Posted In: POAI
